^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Testicular Cancer

Related cancers:
2d
Targeting the LINC01272-FUS signal axis inhibits the migration and invasion of testicular germ cell tumors. (PubMed, Cancer Cell Int)
We identified the LINC01272-FUS axis as a critical regulatory pathway in TGCTs progression, providing mechanistic insights for developing liquid biopsy biomarkers and RNA-targeted therapies.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • VIM (Vimentin) • FUS (FUS RNA Binding Protein) • CDH2 (Cadherin 2) • LAMA1 (Laminin Subunit Alpha 1)
|
TMB-L
3d
Immunotherapy for urological cancers in 2025 (PubMed, Magy Onkol)
By 2025, immunotherapy has become the therapeutic basis for UC and RCC, both in metastatic and curative treatments. In PCa and TGCT, immunotherapy options remain in the experimental phase, but research is ongoing with new combinations and biomarker-driven strategies.
Review • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • cisplatin • Padcev (enfortumab vedotin-ejfv)
3d
Molecular pathology of testicular germ cell tumours: an update for practicing pathologists. (PubMed, Histopathology)
Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations...Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • MDM2 (E3 ubiquitin protein ligase) • AFP (Alpha-fetoprotein) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1)
|
TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • KIT mutation • RAS mutation • KRAS G12
|
cisplatin
3d
Pan-cancer analysis of the oncogenic role of SRY-related high-mobility group box protein B5 in human tumors. (PubMed, Exp Ther Med)
Moreover, SOX5 was associated with genomic instability, susceptibility to medicines such as azacitidine and distinct mutation patterns. SOX5 suppression in NSCLC cells in vitro impeded proliferation, migration and invasion. These findings collectively emphasize the key function of SOX5 in tumor biology and highlight its potential as a biomarker for cancer diagnosis, prognosis and therapeutic targeting.
Journal • PD(L)-1 Biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
azacitidine
5d
Characterizing Paratesticular Neoplasms in Proteus Syndrome. (PubMed, Am J Surg Pathol)
All 7/7 sequenced tumors harbored the AKT1 c.49G>A variant with no additional oncogenic alterations identified by exome sequencing. This series is the largest series to date documenting the clinicopathologic features of paratesticular tumors, a poorly understood component of the Proteus syndrome phenotype.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • WT1 (WT1 Transcription Factor) • PAX8 (Paired box 8)
5d
Pulmonary metastasis from adult-type granulosa cell tumor of the testis: a rare case report and literature review. (PubMed, Curr Med Res Opin)
Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients.
Journal • PD(L)-1 Biomarker
|
FOXL2 (Forkhead Box L2)
|
carboplatin • Focus V (anlotinib) • doxorubicin hydrochloride • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ifosfamide • dacarbazine
6d
Expression of periostin and podoplanin in canine testicular tumours. (PubMed, BMC Vet Res)
The results showed the absence of expression of POSTN and PDPN in normal canine testes and their expression in neoplastic ones, suggesting a role for these proteins in the carcinogenesis of the testis and encouraging further studies, in particular, on seminomas and Sertoli cell tumours.
Journal
|
POSTN (Periostin)
7d
Germ cell immunoprofile and KIT exon 17 mutation guide rectification of seminoma misclassified as epithelioid gastrointestinal stromal tumor: A case report. (PubMed, Biomed Rep)
Definitive diagnosis of seminoma was established through expanded immunohistochemistry (OCT4+/SALL4+/PLAP+/D2-40+) and molecular confirmation of the characteristic KIT p.D816Y mutation, which concurrently explains the observed imatinib resistance. In conclusion, the findings of the present study highlighted the imperative of integrating morphology, immunohistochemistry and context-specific molecular profiling to avoid diagnostic in CD117-positive tumors.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • ALPP (Alkaline Phosphatase, Placental) • POU5F1 (POU Class 5 Homeobox 1) • SALL4 (Spalt Like Transcription Factor 4)
|
KIT mutation
|
imatinib
7d
Primary testicular diffuse large B-cell lymphoma with gonadal vein tumor thrombus: A case report and review of the literature. (PubMed, World J Clin Oncol)
This case demonstrates the diagnostic complexities of PTL with gonadal vein tumor thrombus, underscoring the importance of considering lymphoma in elderly patients with testicular masses and venous involvement. A multi-disciplinary team including urologists, hematologists, and radiation oncologists is needed to ensure appropriate therapy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • IRF4 (Interferon regulatory factor 4)
|
Rituxan (rituximab) • cyclophosphamide • epirubicin • Polivy (polatuzumab vedotin-piiq)
9d
Platinum-Based Chemotherapeutics in the Modern Era: From Classical DNA-Targeting Mechanisms to Next-Generation Innovations in Cancer Therapy. (PubMed, Chem Biol Drug Des)
In order to address the enduring problems of toxicity, resistance, and restricted selectivity, this study charts their development from the traditional agents cisplatin, carboplatin, and oxaliplatin to next-generation developments. Looking forward, integration with CRISPR, 3D tumor modeling, and epigenetic targeting heralds a new frontier, supported by interdisciplinary collaboration bridging chemistry, biology, and technology. This convergence of foundational principles and cutting-edge innovations positions platinum therapy for a transformative era, promising enhanced precision, efficacy, and equity in cancer care worldwide.
Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BRCA (Breast cancer early onset)
|
cisplatin • carboplatin • oxaliplatin
11d
Multi-omics highlights the impacts of cryptorchidism history on immune microenvironment variation in TGCT. (PubMed, Discov Oncol)
We revealed unique molecular pathways in TGCT samples with cryptorchidism history and identified tumor-related features in cryptorchidism accumulation. Cryptorchidism history significantly remodels the immune microenvironment of TGCT.
Journal
|
IFI16 (Interferon Gamma Inducible Protein 16)
13d
The TASTY-steering Study (clinicaltrials.gov)
P=N/A, N=201, Recruiting, University Medical Center Groningen
New trial